The Effect Of Menatetrenone, A Vitamin K2 Analog, On Disease Recurrence And Survival In Patients With Hepatocellular Carcinoma After Curative Treatment: A Pilot Study
Notes for this study:
|Number of Subjects
A pilot study noted that recurrence rates in the group given 45mg MK-4 daily were 12.5% at 12 months, 39.0% at 24 months, and 64.3% at 36 months which significantly outperformed control. The survival rates showed a very strong trend to be improved, but failed to reach statistical significance.